Risky ventures with possibly no returns: the allure of the "wonderful but weird world of biotechnology" by Knowledge@SMU
Singapore Management University
Institutional Knowledge at Singapore Management University
Knowledge@SMU Office of Research & Tech Transfer
5-2011
Risky ventures with possibly no returns: the allure
of the "wonderful but weird world of
biotechnology"
Knowledge@SMU
Follow this and additional works at: https://ink.library.smu.edu.sg/ksmu
Part of the Entrepreneurial and Small Business Operations Commons, and the Technology and
Innovation Commons
This Journal Article is brought to you for free and open access by the Office of Research & Tech Transfer at Institutional Knowledge at Singapore
Management University. It has been accepted for inclusion in Knowledge@SMU by an authorized administrator of Institutional Knowledge at
Singapore Management University. For more information, please email libIR@smu.edu.sg.
Citation
Knowledge@SMU. Risky ventures with possibly no returns: the allure of the "wonderful but weird world of biotechnology". (2011).
Knowledge@SMU.
Available at: https://ink.library.smu.edu.sg/ksmu/173
7/21/12 Risky ventures with possibly no returns: the allure of the "wonderful but weird world of biotechnology…
1/2knowledge.smu.edu.sg/article.cfm?articleid=1351
   
(http://knowledge.smu.edu.sg)
Risky ventures with possibly no returns: the allure of the "wonderful but
weird world of biotechnology"
Published: May 03, 2011 in Knowledge@SMU 
Some people believe that human clones exist in our midst today. Others think that science is not yet so advanced,
but that day will come; and it’s going to be sooner rather than later. In the “wonderful but weird world of
biotechnology”, the potential for amazing discoveries, including those that will make life better, is immense, said Dr
Steven Fang, executive director and Group CEO of the CordLife Group. (http://www.cordlife.com/sg/)
Fang, who was speaking at a recent talk organised by Singapore Management University’s Lee Kong Chian School of
Business (http://www.business.smu.edu.sg/), founded the company in 2001. It provides a range of cord blood and
tissue banking services, which include the collection, processing and cryopreservation of cord blood stem cells and
umbilical tissue. The company, listed on the Australian Stock Exchange, has offices in 37 cities across six countries.
Last year, Cord Life marked a major milestone when it signed up its 25,000th client. 
While not quite among the larger and more famous Singapore-based companies, CordLife is prominent for being a
trailblazer in biotechnology, a fledgling industry relative to the traditional sectors like transport, finance and
manufacturing. Nevertheless, the biotech field can trace its origins back to 1944, when a report noted that DNA
possessed genetic information that could transform the character of cells – a discovery that made waves in the
science community.
Today, biotech is no longer an exotic niche area that interests only white coat scientists who spend all their time
hidden inside laboratories. Biotech, the way Fang describes it, is the integration of many sciences, spanning
agriculture, information technology, pharmaceuticals, medical devices, chemicals and government, to name a few.
The industry’s value chain starts from research and runs through therapeutic targets, intellectual property (IP),
product development, clinical trials and products to market; all of which is supported through grants and
investments. Already, the impact is visible, as seen from the uses and applications of genetically modified organics
and stem cell therapy.
Brave new world?
Still, there is an enigma around biotech as it is considered “a brave new world” that is not yet fully understood. The
risks associated with the unknown perhaps magnifies its allure, for it could well represent an "opportunity to change
the world… to make it a better place,” said Fang. Though biotech has significant potential to contribute to society,
he cautions against going into the business solely for its perceived high returns.
Just like any entrepreneur trying to get a company going, Fang’s initial years were not easy – more so for a company
in a relatively unknown sector that is not easily understood or appreciated by many. In fact, Fang had to rely on the
support of family and friends to get the company off the ground.
With no track record and no profit, “it was extremely difficult to value the company and talk to professional
investors,” he explained. It was only much later that he was able to bring in venture capitalists who were persuaded
by the company’s track record.
Market, silos and ethics
Fang also spoke about the industry's common misconceptions. For one, contrary to the belief that science is all
about proof, facts and reliability, biotech is typically characterised by “profound and persistent uncertainties,” he
said. For example, scientists in green field studies who may not always know what they are working on, often just
record “interesting characteristics and observations”. They only worry about making money later on.
This practice is attributed to “complex and heterogeneous knowledge, and the problem of integration across
industries and fields”. It does not help either that a silo mentality exists within the community as scientists tend to
keep silent about their failures. As such, there is no cumulative learning in the field, he said.
For many biotech companies, a harsh reality is that they may not always be able to achieve breakthroughs in
research and development, which, in turn, directly affects their ability to commercialise. This often causes worry,
not just with shareholders, but also, other downstream (e.g. pharmaceutical) companies that rely on these
advances in research.
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The question of ethics also arises quite often in discussions about biotech, and this is certainly an issue that Fang is
aware of – and has an answer for. “We are not trying to play god; we are helping god,” he explained. “We work with
adult stem cells, not embryonic stem cells.” Unfortunately, in certain societies, ethical regulations have not kept
pace with industry developments. Some organisations thus hide behind “fuzzy differentiations”.
The business of biotechnology
Many fledgling biotech companies, despite their earlier promise, will have to fold once the initial injection of funds
runs dry – and that will usually happen between three and five years. This could be due to failures in distinguishing
between biotech research, and being in the business of biotech research.
The attitude and management capabilities of a “biotechnopreneur” are crucial to the company’s success. Learning to
fail early is important, rather than hanging on hope that the business will pick itself up – which will not happen if the
structure is wrong from the start.
Founders may also tend to be so protective of their “baby” that they do not allow for necessary changes because
they cannot “let go”. The management must be able to transit between phases – that is to move from exploratory
research to development and exploitative phases. This transition can pose a challenge if the management is not
adept at sales and marketing, or lacks the appropriate funding strategy at each stage.
According to Fang, there is no successful company that exists along the whole value chain. The obvious option for
research companies is to outsource or collaborate with companies so as to tap on each others' expertise. The
government’s purpose-built, Agency for Science, Technology and Research (A*STAR) biomedical research hub,
Biopolis, provides this capability as it houses under one roof, like-minded companies along this value chain.
As business is more likely to be conducted over coffee or beer as it is in the boardroom, being in "the right area" and
with "the right community" can make all the difference, said Fang.
Coming of age
A biotechnopreneur must possess industry competencies, and the ability to understand, negotiate and leverage on
the industry's uncertainties. These should be complemented with core organisational capabilities and dynamic
business agility. This includes knowing when to “move in response to technology and market conditions, which is not
too different from running any other company,” said Fang. What is different for biotechnopreneurs and entrepreneurs
is that the former must accept, early on, that "you may never find the right answers".
Meanwhile, as the industry grows in depth, breadth and sophistication, there is a growing number of job
opportunities available throughout the ecosystem and along value chains. These include jobs in areas such as
discovery and research, sales and marketing, support and services, as well as clinical development. “Genomics is
done,” said Fang. Research in the next 10 to 20 years will move beyond genomics to transcriptome and metabolome,
and connectome – the mapping of the human brain. The potential is immense for those who want to be at the
forefront of science.
Obviously, Fang hopes to see his own baby, CordLife, grow. He looks forward to the day when stem cell therapy can
become commonplace, so that it can help more patients. As it is, stem cell therapy tends to be used only as “the
last line of defence”. Cancer patients, for example, would have had to go through other therapies like chemotherapy
or radiotherapy – which have significant side effects and can be draining, emotionally, physically and financially –
before they may be offered stem cell therapy. Alluding to the vast potential, Fang even cited an article which
claimed that when fully deployed and used, biotech can help extend life to 120 years.
Meanwhile, within the foreseeable future, there is a buzzing pipeline of products. For example, yeast is being grown
in space. Also, numerous experiments on animals have shown that it is not inconceivable that human body parts may
be regenerated in the not-too-distant future, Fang noted. “We are at the dawn of scalability” and a lot of the
technology will be going global.  
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